This was the stock's second consecutive day of losses.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

The stock's fall snapped a four-day winning streak.

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...